Stephens Inc. AR Buys New Position in Azenta, Inc. (NASDAQ:AZTA)

Stephens Inc. AR purchased a new position in Azenta, Inc. (NASDAQ:AZTA) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 6,261 shares of the company’s stock, valued at approximately $313,000.

A number of other large investors also recently modified their holdings of AZTA. Sanctuary Advisors LLC acquired a new position in Azenta during the 2nd quarter valued at $222,000. Net Worth Advisory Group acquired a new position in shares of Azenta during the third quarter valued at about $205,000. Allspring Global Investments Holdings LLC lifted its stake in shares of Azenta by 16.4% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,298,856 shares of the company’s stock valued at $62,917,000 after buying an additional 183,040 shares during the period. Nisa Investment Advisors LLC grew its position in Azenta by 1.9% during the third quarter. Nisa Investment Advisors LLC now owns 36,710 shares of the company’s stock worth $1,778,000 after buying an additional 700 shares in the last quarter. Finally, Farther Finance Advisors LLC increased its stake in Azenta by 20.0% during the third quarter. Farther Finance Advisors LLC now owns 1,537 shares of the company’s stock valued at $74,000 after acquiring an additional 256 shares during the period. 99.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

AZTA has been the subject of a number of research reports. Evercore ISI raised their price objective on Azenta from $50.00 to $52.00 and gave the stock an “in-line” rating in a research report on Thursday, February 6th. Stephens reaffirmed an “overweight” rating and issued a $60.00 target price on shares of Azenta in a research report on Thursday, January 2nd. Finally, Needham & Company LLC boosted their price target on shares of Azenta from $55.00 to $59.00 and gave the company a “buy” rating in a report on Thursday, February 6th.

Insider Activity at Azenta

In other Azenta news, CEO John Marotta purchased 12,717 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were acquired at an average cost of $39.48 per share, with a total value of $502,067.16. Following the completion of the transaction, the chief executive officer now owns 99,612 shares in the company, valued at $3,932,681.76. The trade was a 14.63 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William L. Cornog bought 12,500 shares of the business’s stock in a transaction dated Monday, November 18th. The shares were bought at an average price of $39.60 per share, with a total value of $495,000.00. Following the completion of the transaction, the director now owns 14,755 shares in the company, valued at approximately $584,298. This trade represents a 554.32 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 1,423 shares of company stock worth $57,020. Insiders own 10.62% of the company’s stock.

Azenta Trading Up 0.7 %

AZTA stock opened at $45.41 on Friday. Azenta, Inc. has a 1-year low of $38.82 and a 1-year high of $67.77. The firm has a market cap of $2.07 billion, a PE ratio of -15.24 and a beta of 1.47. The business’s 50-day moving average price is $50.56 and its two-hundred day moving average price is $48.51.

Azenta (NASDAQ:AZTA) last posted its earnings results on Wednesday, February 5th. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.05 by $0.03. Azenta had a positive return on equity of 1.25% and a negative net margin of 24.91%. On average, analysts forecast that Azenta, Inc. will post 0.42 earnings per share for the current year.

About Azenta

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.